← All countries · Western Pacific
92%
MCV1
2025 · WHO/UNICEF estimate
91%
DTP3
2025 · WHO/UNICEF estimate
98%
IPV complete
2025 · WHO/UNICEF estimate
95%
HepB3
2025 · WHO/UNICEF estimate
265
Measles cases
2025 reported
89,577
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 98%2025 · WHO/UNICEF estimate | 97.7% | B · good | |
| DTP1First dose of diphtheria-tetanus-pertussis | 91%2025 · WHO/UNICEF estimate | 91.3% | B · good | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 91%2025 · WHO/UNICEF estimate | 91.0% | B · good | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 96.5% | B · good | |
| IPV completeInactivated polio vaccine, complete primary series | 98%2025 · WHO/UNICEF estimate | 96.3% | D · poor | |
| MCV1First dose of measles-containing vaccine | 92%2025 · WHO/UNICEF estimate | 92.2% | B · good | |
| MCV2Second dose of measles-containing vaccine | 95%2025 · WHO/UNICEF estimate | 95.1% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 92%2025 · WHO/UNICEF estimate | 92.2% | B · good | |
| HepB3Third dose of hepatitis B vaccine | 95%2025 · WHO/UNICEF estimate | 94.7% | D · poor | |
| HepB birthHepatitis B birth dose within 24 hours | —% · Administrative (country-reported) | — | too few points | no data |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 96%2025 · WHO/UNICEF estimate | 95.8% | B · good | |
| PCV1Pneumococcal conjugate vaccine, first dose | 96.4%2025 · Administrative (country-reported) | 96.4% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 96%2025 · WHO/UNICEF estimate | 95.9% | B · good | |
| RotaCRotavirus vaccine, complete series | 94%2025 · WHO/UNICEF estimate | 94.0% | C · weak | |
| Yellow feverYellow fever vaccine (countries at risk) | 0%1996 · Administrative (country-reported) | 0% | too few points | D · poor |
| MenAMeningococcal A conjugate (meningitis belt) | —% · Administrative (country-reported) | — | too few points | no data |
| JEJapanese encephalitis vaccine (countries at risk) | 98.2%2025 · Administrative (country-reported) | 98.2% | D · poor | |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | —% · Administrative (country-reported) | — | too few points | no data |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 49%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 30%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | —% · Administrative (country-reported) | — | too few points | no data |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 2652025 | 2.2per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 122025 | 0.1per 1,000,000 total population | B · good | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | B · good | |
| Mumps all countries · vaccine evidence | 6,4312025 | 52.2per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 89,5772025 | 727.7per 1,000,000 total population | B · good | |
| Diphtheria all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Tetanus (total) all countries · vaccine evidence | 942025 | 0.8per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | C · weak | |
| Polio (paralytic) all countries · vaccine evidence | 02021 | 0per 1,000,000 <15 population | D · poor | |
| Yellow fever all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 42025 | 0per 1,000,000 total population | B · good | |
| Invasive meningococcal disease all countries · vaccine evidence | 862025 | 0.7per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 402025 | 0.3per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (47 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | M5-M7 | General/routine | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Older adults with chronic conditions | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 5 | Y11 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 1 | M2 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 2 | M3 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 3 | M4 | General/routine | |
| DTAPHIBIPVDTaP-Hib-IPV (acellular) vaccine | 4 | Y1 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | M2 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 2 | M3 | General/routine | |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 3 | M7 | General/routine | |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 1 | Y13 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 2 | +M1 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV2HPV-2 (Human papillomavirus 2-valent) vaccine | 3 | +M6 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y13 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M2 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 3 | +M6 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 1 | Y13 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| HPV9HPV-9 (Human papillomavirus 9-valent) vaccine | 2 | +M6 | HPV for females only | Y13 - Present routine vaccination of HPV is targeted for only females. |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >=Y65 | Adults | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 1 | M36 | General/routine | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 2 | M37 | General/routine | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 3 | Y4 | General/routine | |
| JE_INACTDJE-Inact (Japanese Encephalitis inactivated) vaccine | 4 | Y9 | General/routine | |
| MRMR (Measles and rubella) vaccine | 1 | Y1 | General/routine | |
| MRMR (Measles and rubella) vaccine | 2 | Y5 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 1 | M2 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 2 | M3 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 3 | M4 | General/routine | |
| PCV20PCV-20 (Pneumococcal conjugate vaccine 20-valent) vaccine | 4 | Y1 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 1 | M2 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 2 | M3 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 3 | M4 | General/routine | |
| PCV_15_VALENTPCV-15 (Pneumococcal conjugate vaccine 15-valent) vaccine | 4 | Y1 | General/routine | |
| PPV23PPV-23 (Pneumococcal polysaccharide 23-valent) vaccine | 1 | Y65 | Adults | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M3 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 2 | M3 | General/routine | |
| ROTAVIRUS_5RV-5 (Rotavirus 5-valent) vaccine | 3 | M4 | General/routine | |
| VARICELLAVaricella vaccine | 1 | M12 | General/routine | |
| VARICELLAVaricella vaccine | 2 | M18 | General/routine | |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Y65 | Adults | Live attenuated vaccines require one dose, while inactivated vaccines require two doses.Persons with Immunocompromised persons during 60-65 years old (Five-year transitional measure: ages 65, 70, 75, 80, 85, 90, 95, and 100 years or older) |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 1 | Y60-Y65 | Risk group(s) | Live attenuated vaccines require one dose, while inactivated vaccines require two doses.Persons with Immunocompromised persons during 60-65 years old (Five-year transitional measure: ages 65, 70, 75, 80, 85, 90, 95, and 100 years or older) |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2 | Adults | Live attenuated vaccines require one dose, while inactivated vaccines require two doses.Persons with Immunocompromised persons during 60-65 years old (Five-year transitional measure: ages 65, 70, 75, 80, 85, 90, 95, and 100 years or older) |
| ZOSTERShingles (Herpes zoster for older adults) vaccine | 2 | +M2 | Risk group(s) | Live attenuated vaccines require one dose, while inactivated vaccines require two doses.Persons with Immunocompromised persons during 60-65 years old (Five-year transitional measure: ages 65, 70, 75, 80, 85, 90, 95, and 100 years or older) |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.